Uterine Neoplasms Clinical Trial
Official title:
Prospective Cohort Study Evaluating Identification Rate of Sentinel Node in the Management of Endometrial Cancer Utilizing a Combined Method of Cervical and Myometrial Injections
The purpose of this study is to determine if there is a difference between the lymphatic drainage of the cervix and corpus of the uterus after injecting a radiocolloid in the cervix and blue dye in the corpus of the uterus and to investigate the identification rate of sentinel nodes using this technique in patients with cancer of the uterus.
About 20 percent of women diagnosed with uterine cancer have spread outside of the uterus,
mainly to the lymph nodes. If these metastases are recognized these women can still be cured
with chemotherapy and radiation. Unfortunately different kind of imaging are not very
sensitive in identifying patients with lymph node metastases and currently a complete
removal of the lymph nodes in the pelvis and around the aorta is the gold standard
diagnostic test. Sentinel node biopsy (SLNB) is a surgical technique that aims to identify
the nodes that drain specifically the area were the tumor is located. A tracer is injected
around the tumor and then the locoregional lymph nodes are tested for the presence of this
tracer (blue dye and a radioactive substance). If the sentinel lymph node does not contain
cancer, then there is a high likelihood that the cancer has not spread to any other area of
the body.The benefits of doing sentinel node biopsy is that it decreases the potential
complications associated with the removal of all the lymph nodes. This technique is the
standard treatment for other cancers as breast cancer and melanoma and is emerging as a
promising technique in gynecological cancers.
There is no agreement regarding the best technique to do SLNB in women with uterine cancer
and this procedure is still at the stage of determining feasibility. Since 1996, there have
been publications aiming to determine the most appropriate way to do sentinel node in
uterine cancer. As the uterus cannot be reached preoperatively for tracer injection, the
standard approach for other tumor sites of preoperative peritumoral injection of Technetium
99 followed by intraoperative injection of blue dye has needed to be modified. Blue dye with
or without a radiocolloid have been administered either subserously (the uterus outer
layer), cervically, dually, and hysteroscopically with a wide range of results in terms of
identification rates of sentinel nodes. Certain factors as site of injection, volume and
number of injections, interval time since injection to identification of sentinel nodes and
surgical approach as laparotomy versus laparoscopy have been associated with the likelihood
of identifying these nodes.
This study plans to determine the pattern of lymphatic drainage for the cervix and corpus of
the uterus by injecting a different tracer in these 2 sites and also to incorporate all
factors that have been proved to be associated with a better identification rate of sentinel
nodes in a protocol in order to determine if this technique is feasible and reliable.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT04063072 -
ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy.
|
N/A | |
Terminated |
NCT01969396 -
Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology
|
N/A | |
Terminated |
NCT00669422 -
ChemoFx® PRO - A Post-Market Data Collection Study
|
N/A | |
Completed |
NCT00231855 -
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
|
Phase 2 | |
Completed |
NCT04679675 -
Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
|
N/A | |
Completed |
NCT04351139 -
Impact of the COVID-19 Pandemic in Gynecological Oncology
|
||
Completed |
NCT05004623 -
Early Feasibility Study of the "Easy Light" Fluorecence Imaging System
|
N/A | |
Completed |
NCT00112307 -
Magnetic Resonance Imaging Guided Gynecologic Brachytherapy
|
N/A | |
Completed |
NCT02454036 -
Biobehavioral Intervention in Gynecologic Oncology Patients
|
Phase 2 | |
Completed |
NCT00188578 -
Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03951415 -
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01654458 -
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
|
N/A | |
Completed |
NCT00190918 -
A Trial for Patients With Gestational Trophoblastic Disease
|
Phase 2 | |
Completed |
NCT00050440 -
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00250783 -
Pre-Clinical Models in Gynecological Tumors A Tissue Repository
|
||
Recruiting |
NCT03624712 -
Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms
|
||
Completed |
NCT00628901 -
A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)
|
Phase 4 | |
Completed |
NCT00090389 -
Acupuncture for Women's Health Conditions
|
Phase 1 |